Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| - | - | - |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| - | - | - |
Zeno Investment Fund's largest holding, Danaher, exemplifies how founder-led ownership creates superior long-term value through strategic transformation. Over 40 years, the Rales brothers evolved Danaher from a 1980s conglomerate into a pure-play bioprocessing, life sciences and diagnostics leader, compounding at 21% annually since 1984. Unlike typical executive-led companies that optimize for short-term metrics, Danaher's founders made bold decisions from positions of strength, spinning off profitable but lower-growth industrial businesses while acquiring high-quality assets like Pall Systems and GE Biopharma. This transformation required abandoning a successful playbook when marginal returns on capital declined, demonstrating true ownership mentality. The company's systematic execution through the Danaher Business System, combined with patient capital allocation focused on market power and organic growth opportunities, positions it for continued outperformance. The manager believes investing in companies with this founder mindset improves odds of long-term success by aligning decision-making with generational wealth creation rather than quarterly performance optimization.
Investing in companies with founder mindset and long-term ownership alignment, exemplified by Danaher's transformation from diversified conglomerate to pure-play bioprocessing leader, creates superior risk-adjusted returns through patient capital allocation and strategic business portfolio optimization.
The manager views Danaher 4.0 as a great investment opportunity, expressing confidence that shareholders are much better off after the transformation compared to where the company would have been without these changes.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 21 2026 | 2025 Q4 | BRK-A, DHR, FTV, GE, ITW, JCI, NVST, VRLT | Biotechnology, Capital Allocation, Conglomerates, Ownership, Spin-Offs, value creation | DHR | Danaher has transformed into a pure play Bioprocessing, Life Sciences and Diagnostics business through strategic acquisitions and spin-offs. The company acquired Pall Systems for $14 billion to gain foothold in bioprocessing space and later acquired GE Biopharma, focusing on manufacturing and sales of consumables and equipment used in production of biotech drugs. The letter discusses how executives typically monetize stock options regularly in the market through stock ownership programs, contrasting this with founder-owners who maintain substantial long-term shareholdings. This highlights different approaches to capital allocation and ownership alignment. |
| Oct 21 2025 | 2025 Q3 | - | Compounding, Governance, Incentives, Leadership, Ownership | - | Zeno reflects on the long-term success of founder-led businesses where execution and risk management coexist. The letter critiques modern executive compensation structures that promote short-termism, contrasting them with owner-operator models at firms like Ryanair and Amphenol. Zeno sees enduring investment value in companies with aligned leadership and ownership cultures. |
| Jun 30 2025 | 2025 Q2 | - | - | TXN | |
| Mar 31 2025 | 2025 Q1 | - | - | - | |
| Dec 31 2024 | 2024 Q4 | - | - | - | |
| Sep 30 2024 | 2024 Q3 | - | - | - | |
| Jun 30 2024 | 2024 Q2 | - | - | - | |
| Mar 31 2024 | 2024 Q1 | - | - | - | |
| Dec 31 2023 | 2023 Q4 | - | - | - | |
| Nov 30 2023 | 2023 Q3 | - | - | - | |
| Jul 18 2023 | 2023 Q2 | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
BuybacksShare repurchases in 2024 and 2025 hit consecutive records as companies raced to meet Tokyo Stock Exchange capital efficiency mandates. Buybacks were a primary driver of the market's 20% climb in the first half of FY2025. |
Share Repurchases Capital Efficiency TSE Mandates Shareholder Returns Records |
TechnologyHoldings span social media, online search, cloud computing and e-commerce including select Magnificent 7 positions. They also own semiconductor companies at reasonable valuations, including picks and shovels businesses like Applied Materials with strong competitive positions and long track records of value creation. |
Technology Semiconductors Cloud Social Media E-commerce | |
| 2025 Q3 |
BiotechBiotech companies rallied over 25% in the fourth quarter, driven by a series of high-profile biotech acquisitions by large pharma buyers. The managers generally avoid biotech stocks due to their highly binary nature, though they participate through investments in companies that sell products and services to biotech customers. |
Biotechnology Pharmaceuticals M&A Healthcare Binary Risk |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | Fund Letters | Cristiano Souza | TXN | Texas Instruments Incorporated | Information Technology | Semiconductors | Bull | NASDAQ | Analog Semiconductors, capital expenditure, Catalog Chips, Free Cash Flow Growth, Supply Chain Security, US Manufacturing, vertical integration | Login |
| Jan 21, 2026 | Fund Letters | Cristiano Souza | DHR | Danaher Corporation | Health Care | Life Sciences Tools & Services | Bull | New York Stock Exchange | Capitalallocation, compounding, Governance, Ownership, Spinoffs | Login |
| TICKER | COMMENTARY |
|---|---|
| BRK-A | Miles mentioned that he had been a long-term shareholder of Berkshire Hathaway and had never sold his shares. Over roughly twenty-five years, his investment compounded at about 10.9% annually. The first dollar he invested became approximately thirteen dollars. Since around 1990, Berkshire has only marginally outperformed the S&P 500. By Buffett's own historical standards, this period could be described as mediocre. And yet, admiration for Buffett has not faded—if anything, it has intensified. |
| DHR | After lagging through the first three quarters of 2025, Danaher's stock rebounded during Q4 as bioprocessing, life science, and diagnostics demand continued to recover from a cyclical trough. On the 3Q25 call, management established conservative 2026 growth expectations. Revenue is expected to continue to lag long-term trends at 3-6% but improve throughout the year. |
| GE | For insight into the real economy operating beneath this AI and data center boom, we must look elsewhere within the S&P 500, including bellwethers like General Electric |
| ITW | Names like Berkshire Hathaway, Johnson Controls, ITW, GE or United Technologies pale in comparison. |
| JCI | We exited Johnson Controls, where we have seen strong datacentre sales, but where the residential segment has been impacted by oversupply, with de-stocking expected to continue into 2026 before normalising again. |
| NVST | Envista Holdings Corp. 2.43% |
| VRLT | Finally, in 2023, Danaher spun off its Environmental and Applied Solutions business into a new public company called Veralto. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||